UPDATE: Citi Upgrades CRISPR Therapeutics (CRSP) to Neutral
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Citi analyst Yigal Nochomovitz upgraded CRISPR Therapeutics (NASDAQ: CRSP) from Sell to Neutral with a price target of $132.00 (from $55.00).
The analyst comments "Last year we outlined three specific reasons (see The View from a Skeptic – Reiterating Sell) why we believed that durability of fetal hemoglobin (HbF) increases for CTX001 in both sickle-cell and beta-thalassemia would not be sustainable over time, thereby placing CRSP’s objective of developing a one-time therapy for both diseases in jeopardy. We have been waiting for the other shoe to drop on durability and have hesitated to conclude that our thesis is being proven wrong. However, with today’s data in more patients and with meaningful follow-up (up to 26 months), it is becoming increasingly clear to us that CTX001 is demonstrating consistent durable increases in HbF that are yielding prolonged therapeutic benefit on transfusion independence in beta-thalassemia and freedom from VOCs in sickle-cell. We are therefore upwardly revising our valuation assumptions to reflect lower risk to future revenues, which takes our target to $132 and we’re upgrading to Neutral."
Shares of CRISPR Therapeutics closed at $123.71 yesterday.
You May Also Be Interested In
- Computershare Limited (CPU:AU) (CMSQY) PT Raised to AUD17.60 at Morgan Stanley
- Towngas China Co Ltd. (1083:HK) (TGASF) PT Raised to HK$6.70 at HSBC
- Iluka Resources Ltd (ILU:AU) (ILKAF) PT Raised to AUD8.20 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!